Fellow GU Lecture Series, Testicular Cancer. Asit Paul, MD, PhD 02/06/2018
|
|
- Christopher Warren
- 6 years ago
- Views:
Transcription
1 Fellow GU Lecture Series, 2018 Testicular Cancer Asit Paul, MD, PhD 02/06/2018
2 Rare cancer worldwide, approximately 1% of all male cancers There is a large difference among ethnic/racial groups. Rates are increasing in Northern Europe and USA Most commonly diagnosed cancer among men in USA, aged years 95% of testicular tumors are germ cell tumors (GCT). GCTs also occur outside testes, such as in retroperitoneum, mediastinum & CNS (pineal/ supra-seller) (5-10%) Cure rate is 100% in stage 1 and >80% in metastatic disease
3 Incidence per /year-men ( ) Incidence is highest in Northern Europe/ Scandanivia and lowest in Asia-Africa
4 SEER DATA, USA Estimated new case in % of new cases in % % of all cancer death in % 5-year survival in % 5-year survival in % Median age at diagnosis ( ) 33 years
5
6 Risk Factors for GCTs White race: X4-5 risk than black Male with Single nucleotide polymorphism in KITLG, seen in white male Crypto-orchidism: X 5-6 risk than normal counterpart Up to 10% patients have undescended testes Risks higher for both undescended & descended testes Orchioplexy reduces risk Family Hx: X2-4 risk in father, X5-9 in brother Personal hx of testicular cancer Intratubular germ cell neoplasia Testicular dysgenesis HIV Kleinfelter syndrome (mediastinal GCT)
7 Testicular Tumors: Classification Germ cell tumors (95%) Seminoma Non-seminoma: mixed subtype Embryonal cell CA, Choriocarcinoma, Yolksac tumor, teratoma (mature & immature) Non-GCTs: Sex-cord stromal tumors Secondary Lymphoma, Sarcoma Leukemic infiltration Metastatic
8 Non-seminomatous GCT Most NSGCTs contain 2 or more histologic subtypes When NSCGT contain one histology- embryonal carcinoma is the most frequent. Embryonal carcinoma is the most undifferentiated subtype and can differentiate into other NSGCT histology Choriocarcinomas contain both syncytiotrophoblasts and cytotrophoblasts Mature teratoma is histologically benign Teratoma can progress locally or transform into a somatic malignancy ( TMT) such as sarcoma, PNET, adenocarcimoma or hem-malignancies
9 Clinical Presentation Painless testicular mass Retroperitoneal LN (L>R) is the most common metastatic site Lung is the most common visceral site of metastasis Initial Work-up: USG of testes, Tumor markers, CT A/P, Chest imaging. Bone scan & brain imaging in selective cases USG of testes should be done in all cases. Orchiectomy should be the initial management in all cases of testicular primary at presentation.
10 Serum tumor markers Serum Markers Half-life Tumor subtype B-HCG h Seminoma, Non-Seminoma AFP 5-7 days Non-seminoma LDH 24 h Not specific, reflects volume B-HCG is secreted by both seminoma and non-seminoma. Elevated HCG is present in 15% of stage 1 seminoma, 50% of metastatic seminoma & 40-60% of non-seminoma Pure chorio-carcinomas have a very high HCG level AFP is never secreted by pure seminoma & choriocarcinoma Elevated AFP is present in 50-60% of non-seminoma. Elevated AFP, irrespective of histology, is considered diagnostic of non-seminoma Yolk sac tumors have high-level of AFP Embryonal carcinomas typically have rise in all 3 tumor markers
11 Isochromosome 12p or other form of 12p amplification is seen in vast majority of cancers of testicular origin, irrespective of histologic subtypes Kernek, Modern Pathology, 2004
12 Risk Non-seminoma Seminoma 5 Y PFS 5 Y OS 5 Y PFS 5Y OS Good 89% 92% 82% 86% Inter 75% 80% 67% 72% Poor 41% 48% Based on 5,202 NSGCT & 660 seminoma patients. Median FU 5 years. Post-orchiectomy markers are used for risk stratification J Clin Oncol 1997
13 Management: depends on stage, risk & disease course Inguinal Orchiectomy Surveillance, adjuvant chemotherapy or radiation for stage 1 seminoma Retroperitoneal LN dissection Chemotherapy (BEP) for advance stage, rising marker, recurrence High-dose chemotherapy with autologous stem cell transplant for refractory cancers Surveillance after treatment
14 Upfront Management of Seminoma after Orchiectomy
15 Pure Seminoma: Stage I (No LN or distant metastasis) 80% of seminomas are stage I. Treatment after post-orchiectomy normalization of markers, include active surveillance, adjuvant radiation or chemotherapy NCCN recommends active surveillance as a preferred treatment after orchiectomy (category 1). NCCN has category 2A recommendations for adjuvant carboplatin (AUC 7, 1-2 cycles) or radiation (20 Gy in 10 F) >98% can be cured regardless of type of therapy 5 year relapse rates: 20% with surveillance vs. 4-9% with adjuvant carboplatin Studies showing tumors (>4 cm) or rete testes involvement as a high-risk factors are not confirmed by subsequent studies
16 Pure seminoma Stage II: LN involvement Low-volume disease (Stage IIA: LN < 2 cm): Normal Markers: repeat scan (6-8 wk)/ Bx Elevated markers-> radiation or chemotherapy LN >2-5 cm or multiple positive nodes (stage IIB) Chemotherapy: EP X4 or BEP X 3 Post chemotherapy management*
17 Pure Seminoma: Stage IIC (LN>5 cm or III visceral metastasis) IGCCCC risk stratification Good risk: BEP X3 or EP X4 Intermediate risk BEP X4 (NCCN 1) or VIP (NCCN 2A) Post-chemotherapy management
18 Management of Non-seminoma
19 Stage I Non-seminoma Options include surveillance, RPLND & BEP (X1-2) No survival advantage with adjuvant Rx. Recurrence is generally within 2-3 y of orchiectomy. Can be salvaged effectively with chemotherapy 80-85% of stage 1A are cured by orcheictomy alone. Patient with LVI are at high risk of recurrence, 45-55% (LVI) vs 20-25% (no LVI) Primary RPLND is offered to +LVI, pt2-t4, noncompliant & predominantly embryonal carcinoma patients Chemotherapy is offered to those whose postorchiechtomy markers are not normalized
20 Non-seminoma: LN or visceral met Markers * Metastasis Treatment options Normalized LN 2 cm (N1) LN 2-5 cm (N2) RPLND or Chemotherapy** Chemotherapy* or RPLND in selected cases LN >5 cm (N3) BEP X 4 or VIP X 4 Not normalized Visceral metastasis/ Intermediate/ High risk BEP X 4 or VIP X 4 Stage II-III BEP X4 of VIP X 4 * Markers: post-orchiectomy, ** BEP X 3 or EP 4
21 Post-chemotherapy management with normal markers Residual disease Seminoma LN 3 cm Surveillance Seminoma LN > 3 cm PET +ve: RPLND PET ve: Surveillance Nonseminoma LN 1 cm Surveillance Nonseminoma LN > 1 cm Tumor markers not normalized No role of PET, RPLND Salvage chemotherapy
22 Post-chemo residual masses: Role of imaging PET has high NPV, but poor PPV in seminoma PET should be done >6 weeks after completion of chemotherapy in seminoma RPLND in seminoma is a difficult surgery & should be done in tertiary centers Equivocal PET should be repeated PET has no role in non-seminoma CT should be done 3-4 weeks after chemo in nonseminoma Post-chemo NSGCT bx showed 40% necrosis, 40% teratoma & 20% viable carcinoma. RPLND should be done in all tumors >1 cm in size.
23 Chemotherapy for GCTs Regimen Comment 1 st line BEP Preferred 1 st line for good-risk patient EP VIP/ mod TIP/VeIP For good-risk patients Bleo sparing, considered for poorrisk patients 2 nd line conventional VeIP/ TIP Growth factor support 2 nd line High-dose Paclitaxel/Ifosfomide -> Carbo/etop Palliative Gem-Ox, Gempaclitaxel, Gem-Ox-Pac, oral etop Autostem cell support Palliative Pembrolizumab MSI-H/ d-mmr patients
24 Initial chemotherapy for GCT Numerous trials have shown excellent outcomes of cisplatin-based regimens in good-risk patients with CR >90-95% 4 randomized trials showed superiority of cisplatin over carboplatin based combination regimens Since reduced-dose cisplatin has inferior outcome, dose reduction should be avoided. G-CSF support should be provided after an episode of FN Indiana university and MSK studies showed equivalent outcomes of BEP X 3 & EP X4 cycles in good-risk GCT In poor risk patients, both BEP X4 & VIP X4 are NCCN I recommendations. Recent study has shown TIP has durable response in poor & intermediate risk patients.
25 Overall survival Hinton, Cancer, 2002
26 T: 240 mg/m2 X 2 d, I: 6 g/m2 X 5 d + mesna, P: 100 mg/m2 X 5 d G-CSF, Q 3 W CR rate 68%, 3 y PFS 72% & OS 91%, GIII-IV toxicity: 18% Feldman, J Clin Oncol 2016
27 Salvage therapy after relapse 70-80% patients with mgct can have durable response after 1 st line chemotherapy Patients with incomplete response to 1 st line chemotherapy have suboptimal response to 2 nd line conventional dose chemotherapy 2 nd line TIP chemotherapy has 70% RR in IGCCCG good risk group (Kondagunta, JCO, 2005) At MSKCC, patients with at least 1 poor-risk factor treated with HDCT/SCT (TI-CE) had 5 Y DFS 47% & OS 52% (Feldman, JCO, 2010) Updated data from Indiana University showed patients treated with HDCT/SCT with CE has 2 y OS of 82%, 58% & 43%, for IGCCCG good, intermediate & poor risk category (Adra, JCO, 2017)
28 2 nd line CD chemotherapy Rashdan & Einhorn, JOP, 2016
29 46 patients, Testes primary Non-seminoma 89% All patients had CR or PR with negative marker >6 m to 1 st line chemo Prior BEP 74% IGCCCG good risk at dx 4 cycles of TIP 63% durable CR at 69 m median FU 2 y PFS 65% Kondagunta, JCO, 2005
30 Prospective Phase I/II trial at MSKCC Progressive GCT, after at least 1 cycle of cisplatin based chemotherapy 1 poor prognostic feature: Extragonadal primary, PD after prior salvage CDCT, IR or relapse <6 m after 1 st line, 2 cycles of TI (CD), 14 days apart, followed by 3 cycles of CE with autosct, days apart CR 50%, PR-neg 8%, PR 45% 5 y DFS 47%, OS 52% Mediastinal primary PFS 24%, OS 29% Feldman, J Clin Oncol 2010
31 mgct who relapsed after 1 CD chemo (n=364), 1 st Cycle: Carbo/etop X 3 d -> autosct, after 3 days. 2 nd cycle: After recovery of neutrophil & platelet counts. Oral etoposide daily for 21 days, q 4 W X 3 J Clin Oncol 2017
32 Lorch, J Clin Oncol 2011
33 J Clin Oncol 2010 Pagliaro, J Clin Oncol 2016
34 Who should receive salvage HDCT/ autosct? Initial salvage to all patients (Indiana Univ) Poor risk features (Extra-gonadal primary, progressive dz after CDCT, incomplete response or relapse <6 m of 1 st line (MSKCC) IGCCCG poor risk at relapse 3 rd line setting
35 Pagliaro, J Clin Oncol 2016
36 NCT Standard-Dose Combination Chemotherapy or High- Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors (TIGER) Arm A: Standard TIP X 4 cycles Arm B: TI-CE X 5 cycles TI X 2, q 14 d -> CE (D1-3) SC (D5) X3, q21d
37 Salvage chemo for relapse after HDCT Rashdan & Einhorn, JOP, 2015
38 Special situations Cisplatin-refractory: Progression during or within 4 weeks of cisplatin-based chemotherapy. Should be referred for HDCT Late-relapse: Relapse >2 y of initial Rx. Late relapse in seminoma should be treated same as early relapse. NSGCT should be treated with surgery with or without salvage chemotherapy Elevated tumor markers after initial Rx: Alternative explanation of low-level elevated markers after chemotherapy (such as AFP <25 ng/ml) should be looked for. Rising tumor markers should raise the concern for relapse. LDH alone should never be used as a marker of relapse. Mediastinal NSGCT: Rare entity with worse outcome. Predominantly contain yolk-sac components. 5 y survival is 40-45%. Generally classified as poor-risk category and should be treated with regimens for poor risk disease, such as VIP, TIP or HDCT, followed by resection.
39 Testicular cancer is the most frequent solid tumor in the year age group. Rate of testicular cancer is rising The survival of patients with early stage disease is close to 100% About 70-80% patients with mgct can achieve durable response with cisplatin based regimen. Conventional dose 2 nd - line chemotherapy can provide durable response in 70% of patients who recur after 1 st line chemotherapy HD-chemotherapy with stem cell support can salvage high-risk refractory patients with durable response Ongoing phase III, international TIGER trial is comparing standard dose vs HDCT in relapsed GCT patients (NCT )
40 Survivorship & life issues Fertility issues Hypogonadism Secondary cancers, including leukemia Hearing issues after cisplatin Lung function after cisplatin and bleomycin Cardiovascular effects from radiation & chemotherapy
Fellow GU Lecture Series, Testicular Cancer. Asit Paul, MD, PhD 02/06/2018
Fellow GU Lecture Series, 2018 Testicular Cancer Asit Paul, MD, PhD 02/06/2018 Rare cancer worldwide, approximately 1% of all male cancers There is a large difference among ethnic/racial groups. Rates
More informationNICaN Testicular Germ Cell Tumours SACT protocols
Reference No: Title: Author(s) Ownership: Approval by: Systemic Anti-Cancer Therapy (SACT) Guidelines for Germ Cell Tumours Dr Audrey Fenton Consultant Medical Oncologist, Dr Vicky Coyle Consultant Medical
More informationPoor-prognostic advanced Germ Cell Tumors
14-10-16 Poor-prognostic advanced Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Metastatic GCT: Prognosis (IGCCC) Good prognosis Intermediate prognosis Poor prognosis J Clin Oncol
More informationTESTICULAR CANCER Updated March 2016 by Dr. Safiya Karim (PGY-5 Medical Oncology Resident, University of Toronto)
TESTICULAR CANCER Updated March 2016 by Dr. Safiya Karim (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Aaron Hansen (Staff Medical Oncologist, University of Toronto) DISCLAIMER:
More informationGUIDELINES ON TESTICULAR CANCER
38 (Text updated March 2005) P. Albers (chairman), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, A. Horwich, O. Klepp, M.P. Laguna, G. Pizzocaro Introduction Compared with other types of cancer
More informationTesticular Malignancies /8/15
Collecting Cancer Data: Testis 2014-2015 NAACCR Webinar Series January 8, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationEAU GUIDELINES ON TESTICULAR CANCER
EAU GUIDELINES ON TESTICULAR CANCER (Limited text update March 2018) P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna (Vice-chair), N. Nicolai,
More informationEAU GUIDELINES ON TESTICULAR CANCER
EAU GUIDELINES ON TESTICULAR CANCER (Limited text update March 2015) P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg
More informationGerm Cell Tumors. Karim Fizazi, MD, PhD Institut Gustave Roussy, France
Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Surveillance for stage I GCT NSGCT A 26 year-old patient had a orchiectomy revealing embryonal carcinoma (40%), seminoma (40%) and
More informationGERM-CELL TUMOURS. ESMO Preceptorship on Adolescents and Young Adults with cancer Lugano, May 2018
ESMO Preceptorship on Adolescents and Young Adults with cancer Lugano, 11-12 May 2018 GERM-CELL TUMOURS Giannis Mountzios MSc, PhD Medical Oncology University of Athens School of Medicine Athens, Greece
More informationEAU GUIDELINES ON TESTICULAR CANCER
EU GUIDELINES ON TESTICULR CNCER (Limited text update March 2017) P. lbers (Chair), W. lbrecht, F. lgaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi,. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg Introduction
More informationESMO Consensus Empfehlungen 2017
ESMO Consensus Empfehlungen 2017 What s old, what s new, what s missing? Jörg Beyer, Klinik für Onkologie Offenlegung Interessenskonflikte 1. Anstellungsverhältnis oder Führungsposition Keine 2. Beratungs-
More informationNote: The cause of testicular neoplasms remains unknown
- In the 15- to 34-year-old age group, they are the most common tumors of men. - Tumors of the testis are a heterogeneous group of neoplasms that include: I. Germ cell tumors : 95%; all are malignant.
More informationTesticular Cancer. Prof. Dr. Jörg Beyer Physician-in-Chief Department of Oncology, University Hospital Berne, Switzerland. Mail:
Testicular Cancer Prof. Dr. Jörg Beyer Physician-in-Chief Department of Oncology, University Hospital Berne, Switzerland Mail: joerg.beyer@insel.ch The menue: Epidemiology & Staging Ongoing discussions
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More information-The cause of testicular neoplasms remains unknown
- In the 15- to 34-year-old age group, they are the most common tumors of men. - include: I. Germ cell tumors : (95%); all are malignant. II. Sex cord-stromal tumors: from Sertoli or Leydig cells; usually
More informationManagement of Stage Ic-IV Malignant Ovarian Germ Cell Tumours
Management of Stage Ic-IV Malignant Ovarian Germ Cell Tumours Michael J Seckl Charing Cross Hospital Campus of Imperial College NHS Healthcare Trust Imperial College London, UK 9-12th June 2010 Caravaggio
More informationTesticular cancer and other germ cell tumours. London Cancer Jonathan Shamash
Testicular cancer and other germ cell tumours London Cancer 2018 Jonathan Shamash Background Testicular germ cell tumours are the commonest cancers of young men Overall they are curable but long term side
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation in the Treatment of Germ File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_in_the_treatment_of_germ_cell_tumor
More informationTestis tumors. Richard Epstein
Testis tumors Richard Epstein TKCC/SVH, August 5 2016 Testis cancer - Remains virtually the only solid (nonhaematologic) metastatic tumour that is routinely curable by drug therapy. What we will discuss
More informationMale Genital Cancers in the US in Frequency of Types
Germ Cell Tumors of the Testis Pathology, Immunohistochemistry, and the Often Confusing Appearance of Their Metastases Charles Zaloudek, MD Department of Pathology UCSF Male Genital Cancers in the US in
More informationCitation for published version (APA): Lutke Holzik, M. F. (2007). Genetic predisposition to testicular cancer s.n.
University of Groningen Genetic predisposition to testicular cancer Lutke Holzik, Martijn Frederik IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationQuiz 1. Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios.
Quiz 1 Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios. 1. 62 year old Brazilian female Race 1 Race 2 Spanish/Hispanic Origin 2. 43 year old Asian male born in Japan Race 1
More informationLeukaemia 35% Lymphoma 14%
Distribution ib ti of Cancers in Children under 15 years Leukaemia 35% Lymphoma 14% Neuroblastoma 9% Other 5% Liver 1% Retinoblastoma 3% Bone and STS 15% CNS 20% Wilms' 8% 30-40% Mortality Germ Cell Tumours
More informationTesticular germ cell tumors
Testicular germ cell tumors Introduction Most common solid tumor in young adult men with 3 6 new cases/100,000 men/year. They acc ount for 1.5% of male malignancies and 5% of urological tumors. Bilateral
More informationGuidelines on Testicular Cancer
Guidelines on Testicular Cancer P. Albers (chairman), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna European Association of Urology 2009 TABLE OF CONTENTS
More informationCase Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult
Case Scenario 1 Discharge Summary A 31-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was
More informationProf. Dr. med. Beata BODE-LESNIEWSKA Institute of Pathology and Molecular Pathology University Hospital; Zurich
Prof. Dr. med. Beata BODE-LESNIEWSKA Institute of Pathology and Molecular Pathology University Hospital; Zurich 32 year old man 2 months history of growing left supraclavicular lymph nodes Antibiotic treatment
More informationExercise. Discharge Summary
Exercise Discharge Summary A 32-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was present
More informationCollecting Cancer Data: Testis 2/3/11. Collecting Cancer Data: NAACCR Webinar Series 1. Agenda. Fabulous Prizes
Collecting Cancer Data: Testis February 3, 2011 NAACCR 2010-2011 Webinar Series Agenda Coding moment Race/Hispanic origin Overview Collaborative Stage Treatment Exercises Fabulous Prizes NAACCR 2010-2011
More informationCardiff MRCS OSCE Courses Testicular Cancer
Testicular Cancer Scenario: A 40-year-old male presents to the surgical out-patient clinic with a 6-8 week history of a painless lump in his left scrotum. He however complains of a dull ache in the scrotum
More informationManagement of Testicular Cancer
Management of Testicular Cancer Christian Kollmannsberger MD FRCPC Clinical Professor Div. of Medical Oncology BC Cancer - Vancouver Cancer Centre Dept. of Medicine, University of British Columbia Associate
More informationGUIDELINES ON TESTICULAR CANCER
European Association of Urology GUIDELINES ON TESTICULAR CANCER P. Albers (chairman), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, A. Horwich, O. Klepp, M.P. Laguna, G. Pizzocaro UPDATE MARCH
More informationIntensive Chemotherapy with Autologous Peripheral Blood Stem Cell Transplantation During a 10-Year Period in 64 Patients with Germ Cell Tumor
Biology of Blood and Marrow Transplantation 12:355-365 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1203-0013$32.00/0 doi:10.1016/j.bbmt.2005.11.006 Intensive Chemotherapy
More informationCase Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult
Case Scenario 1 Discharge Summary A 31-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was
More informationSTAGING AND FOLLOW-UP STRATEGIES
ATHENS 4-6 October 2018 European Society of Urogenital Radiology STAGING AND FOLLOW-UP STRATEGIES Ahmet Tuncay Turgut, MD Professor of Radiology Hacettepe University, Faculty of Medicine Ankara 2nd ESUR
More informationHematopoietic Cell Transplantation in the Treatment of Germ Cell Tumors (GCT)
Hematopoietic Cell Transplantation in the Treatment of Germ Cell Tumors (GCT) Policy Number: 8.01.35 Last Review: 7/2017 Origination: 7/2002 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas
More informationChemotherapy for Urological Cancers
Chemotherapy for Urologic Cancers Matthew Rettig, MD Associate Professor Department of Medicine Division of Hematology-Oncology Department of Urology Medical Director, Prostate Cancer Program Institute
More informationPopulations Interventions Comparators Outcomes Individuals: With previously untreated germ cell tumors
Hematopoietic Cell Transplantation in the Treatment of Germ Cell (80135) (Formerly Hematopoietic Stem Cell Transplantation in the Treatment of Germ Cell ) Medical Benefit Effective Date: 04/01/13 Next
More informationLong-Term Outcome for Men With Teratoma Found at Postchemotherapy Retroperitoneal Lymph Node Dissection
Original Article Long-Term Outcome for Men With Teratoma Found at Postchemotherapy Retroperitoneal Lymph Node Dissection Robert S. Svatek, MD 1, Philippe E. Spiess, MD 2, Debasish Sundi, BS 1, Shi-ming
More informationResection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer
Turkish Journal of Cancer Vol.31/ No. 2/2001 Resection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer AHMET ÖZET 1, ALİ AYDIN YAVUZ 1, MURAT BEYZADEOĞLU
More informationMULTIDISCIPLINARY GENITOURINARY ONCOLOGY COURSE
MULTIDISCIPLINARY GENITOURINARY ONCOLOGY COURSE Case 2 Testicular Cancer Nuno Sineiro Vau Medical Oncologist Champalimaud Foundation, Lisbon October 2017 Male, 36 year-old, sales manager. Past medical
More informationLate recurrence of an embryonal carcinoma of the testis. Case report
Late recurrence of an embryonal carcinoma of the testis. Case report Luminita Gurguta 1 *, Mihai V. Marinca 1, 2 1 Medical Oncology Department, Regional Institute of Oncology, Iasi, Romania, 2 Department,
More informationTesticular Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version December 8, NCCN.org.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2017 December 8, 2016 NCCN.org Continue Version 2.2017, 12/08/16 National Comprehensive Cancer Network, Inc. 2016, All rights
More informationProspective study evaluating a strategy of surgery alone and surveillance in FIGO stage I malignant ovarian germ cell tumor (KGOG 3033)
Prospective study evaluating a strategy of surgery alone and surveillance in FIGO stage I malignant ovarian germ cell tumor (KGOG 3033) Investigators/Collaborators: Jeong-Yeol Park, M.D., Ph.D. Department
More informationTwelve Years of Experience in the Management of Testicular Germ Cell Tumors at a Referral Center in Portugal
Elmer Press Original Article Twelve Years of Experience in the Management of Testicular Germ Cell Tumors at a Referral Center in Portugal Diana Valadares a, c, Filipe Nery a, Franklim Marques a, b Abstract
More informationMediastinal Germ Cell Tumors
Mediastinal Germ Cell Tumors Anja C. Roden, M.D. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA 2018 MFMER slide-1 Disclosure I have no relevant financial relationships
More informationViable Germ Cell Tumor at Postchemotherapy Retroperitoneal Lymph Node Dissection. Can We Predict Patients at Risk of Disease Progression?
2700 Viable Germ Cell Tumor at Postchemotherapy Retroperitoneal Lymph Node Dissection Can We Predict Patients at Risk of Disease Progression? Philippe E. Spiess, MD 1 Nizar M. Tannir, MD 2 Shi-Ming Tu,
More informationTeratocarcinoma In A Young Boy- An Unusual Presentation
Human Journals Case Report November 2015 Vol.:2, Issue:1 All rights are reserved by Atia Zaka-ur-Rab et al. Teratocarcinoma In A Young Boy- An Unusual Presentation Keywords: Boy, Testicular Mass, Teratocarcinoma
More informationTesticular Cancer. J. Richard Auman, MD. James J. Stark, MD. Jerry Singer, MD. September 19, 2008
Testicular Cancer J. Richard Auman, MD James J. Stark, MD Jerry Singer, MD September 19, 2008 Testicular Cancer From mystery to far-advanced disease: a remarkable case Case Presentation. 23 y. o. male
More informationHematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors. Original Policy Date
MP 7.03.27 Hematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature
More informationState of the Science: Current status of research relevant to GCT GCT Survivors Weekend April 16, 2011
State of the Science: Current status of research relevant to GCT GCT Survivors Weekend April 16, 2011 Jubilee Brown, M.D. Associate Professor UT M.D. Anderson Cancer Center Ovarian Cancer 21,880 new cases
More informationPage 1 of 17 TABLE OF CONTENTS
Page 1 of 17 TABLE OF CONTENTS Suspicious Testicular Cancer. Page 2 nseminomatous Germ Cell Tumor (NSGCT): workup and clinical stage Page 3 Seminoma: workup and clinical stage... Page 4 Clinical Stage
More informationPatients and methods. Results
Journal of BUON 10: 195-200, 2005 2005 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Germ cell testicular tumors in clinical stage A and normal values of serum tumor markers post-orchiectomy:
More informationTesticular Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2014 NCCN.org Continue Version 1.2014, 12/13/13 National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN
More informationTesticular tumours are uncommon but constitute an
09010:Layout 1 3/18/10 9:26 PM Page E19 CONSENSUS GUIDELINE Canadian consensus guidelines for the management of testicular germ cell cancer Lori Wood, MD; * Christian Kollmannsberger, MD, FRCSC; Michael
More informationANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY
ANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY Note: These surveillance recommendations are provided as recommendations only. Clinicians should take into account
More informationGynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy
Gynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy Stephanie Yap, M.D. University Gynecologic Oncology Northside Cancer Institute Our Learning Objectives Review survival rates,
More informationDonamo GU Testis carcinoom. Andre Bergman & Martijn Kerst, 9 september 2015
Donamo GU Testis carcinoom Andre Bergman & Martijn Kerst, 9 september 2015 Casus Ploegarts Tinkoff-Saxo benadert u met de vraag: Is Adjuvante therapie? raadzaam na inguinale orchidectomie vanwege klinisch
More informationTestis. Protocol applies to all malignant germ cell and malignant sex cord-stromal tumors of the testis, exclusive of paratesticular malignancies.
Testis Protocol applies to all malignant germ cell and malignant sex cord-stromal tumors of the testis, exclusive of paratesticular malignancies. Protocol revision date: January 2005 Based on AJCC/UICC
More informationWhat is Testicular cancer?
Testicular Cancer What is Testicular cancer? Testicular cancer is a disease in which cancer cells form in the tissues of one or both testicles. The testicles are 2 egg-shaped glands located inside the
More informationEuropean consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
Original article Annals of Oncology 15: 1377 1399, 2004 doi:10.1093/annonc/mdh301 European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus
More informationTesticular Cancer: Questions and Answers. Testicular cancer is a disease in which cells become malignant (cancerous) in one or both testicles.
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Testicular Cancer: Questions
More informationMixed Germ Cell Testis Tumor Presenting with Massive Lung Metastasis
International Archives of Medical Research Volume 10, No.1, pp.21-26, 2018. CASE REPORT RESEARCH Mixed Germ Cell Testis Tumor Presenting with Massive Lung Metastasis Zuhat Urakci 1, Senar Ebinc 1, Ogur
More informationTesticular Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version November 2, NCCN.org.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2017 November 2, 2016 NCCN.org Continue Panel Members * Timothy Gilligan, MD/Chair Case Comprehensive Cancer Center/ University
More informationHematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors
Hematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors Policy Number: Original Effective Date: MM.07.020 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 05/24/2013
More informationUncommon secondary tumour of the stomach
Uncommon secondary tumour of the stomach B. Bancel, Hôpital CROIX ROUSSE LYON Bucharest Nov 2013 Case report 33-year old man Profound mental retardation and motor disturbances (sequelae of neonatal meningeal
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationMediastinal tumours. the oncological view. D. Betticher, Medical Oncology, Cantonal Hospital Fribourg, Switzerland
Mediastinal tumours the oncological view D. Betticher, Medical Oncology, Cantonal Hospital Fribourg, Switzerland Mediastinal tumours Clavicula Antero-superior Intermediary Posterior D4 Antero-superior
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Testicular Cancer
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2016 NCCN.org Continue Panel Members * Robert J. Motzer, MD/Chair Þ Memorial Sloan Kettering Cancer Center Steven L. Hancock,
More informationmolecular brothers David Pfisterer Lucerne, Switzerland ESIM 2011
molecular brothers David Pfisterer Lucerne, Switzerland ESIM 2011 Case Vignette A 25-year old man was admitted to our hospital because of fever, productive cough, nausea and weight loss. The patient had
More informationEAU Guidelines on Testicular Cancer
EAU Guidelines on Testicular Cancer P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg Guidelines Associates: J.L.
More informationGerm cell tumours UK SH. Ivo Leuschner. Kiel Pediatric Tumor Registry, Institute of Pathology University Hospital of Schleswig-Holstein Campus Kiel
Germ cell tumours Ivo Leuschner Kiel Pediatric Tumor Registry, Institute of Pathology University Hospital of Schleswig-Holstein Campus Kiel UK SH Old histogenetic Concept of Germ cell tumours Pluripotent
More informationAttachment #2 Overview of Follow-up
Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer
More informationPrimary mediastinal nonseminomatous germ cell tumors
ORIGINAL ARTICLE Resection of Primary Mediastinal Non-Seminomatous Germ Cell Tumors A 28-Year Experience at Memorial Sloan-Kettering Cancer Center Inderpal S. Sarkaria, MD,* Manjit S. Bains, MD,* Shelly
More informationThe Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer
The Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer Isidore Mandelbaum, M.D., Peter B. Yaw, M.D., Lawrence H. Einhorn, M.D., Stephen D. Williams,
More informationSurveillance Alone Versus Radiotherapy After Orchiectomy for Clinical Stage I Nonseminomatous Testicular Cancer
Surveillance Alone Versus Radiotherapy After Orchiectomy for Clinical Stage I Nonseminomatous Testicular Cancer By Mikael Rorth, Grethe Krag Jacobsen, Hans von der Maase, Ebbe Lindegdrd Madsen, Ole Steen
More informationBENIGN & MALIGNANT TESTIS DISEASES. Gary J. Faerber, M.D. Associate Professor, Dept of Urology March 2009 OBJECTIVES
BENIGN & MALIGNANT TESTIS DISEASES Gary J. Faerber, M.D. Associate Professor, Dept of Urology March 2009 OBJECTIVES 1. Become familiar with the scrotal contents and their anatomical relationship with each
More informationTesticular Cancer Update Nabil Adra 1, Lawrence H. Einhorn 1
Review Article - Clinical Advances in Hematology & Oncology Testicular Cancer Update Nabil Adra 1, Lawrence H. Einhorn 1 1 Division of Hematology & Medical Oncology - Melvin & Bren Simon Cancer Center,
More informationBilateral Testicular Germ Cell Tumors
1228 Bilateral Testicular Germ Cell Tumors Twenty-Year Experience at M. D. Anderson Cancer Center Mingxin Che, M.D., Ph.D. 1 Pheroze Tamboli, M.D. 1 Jae Y. Ro, M.D., Ph.D. 1 Dong Soo Park, M.D. 2 Jung
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM GERM CELL TUMOURS CNS Site Group Germ Cell Tumours Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationGerm cell tumors (GCT) are uncommon neoplasms
ORIGINAL ARTICLES: GENERAL THORACIC Pulmonary Metastasectomy for Testicular Germ Cell Tumors: A 28-Year Experience David Liu, MD, Amir Abolhoda, MD, Michael E. Burt, MD, PhD, Nael Martini, MD, Manjit S.
More informationOncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R
Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R 2 0 1 2 Objectives Discuss Diagnostic and staging strategies in oncology Know
More informationChemotherapy Treatment Algorithms for Urology Cancer
Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional
More informationNerve-sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy
Blackwell Science, LtdOxford, UK IJU International Journal of Urology 0919-81722002 Blackwell Science Asia Pty Ltd 910October 2002 520 Postchemotherapy nerve-sparing RPLND N Nonomura et al. 10.1046/j.0919-8172.2002.00520.x
More informationASYMPTOMATIC COMPLEX TESTICULAR NEOPLASIA ASSOCIATED WITH ORCHIEPIDIDYMITIS. CASE REPORT
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2017 vol. 121, no. 4 SURGERY CASE REPORTS ASYMPTOMATIC COMPLEX TESTICULAR NEOPLASIA ASSOCIATED WITH ORCHIEPIDIDYMITIS. CASE REPORT Ș. Iacob 1, R. Vrînceanu 2,3, B.
More informationTesticular Tumors: What s New, True, Important Cristina Magi-Galluzzi, MD, PhD
Testicular Tumors: What s New, True, Important Cristina Magi-Galluzzi, MD, PhD Director, Genitourinary Pathology R.J. Tomsich Pathology & Laboratory Medicine Institute Professor of Pathology, Lerner College
More informationData Supplement Table DS1: Pre-Treatment STM Assays to Evaluate Patients with CUP and Predict Chemotherapy Response
American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males with Germ Cell Tumors Gilligan, et al. SUPPLEMENTAL TABLES DS1-DS13 Data Supplement Table
More informationNCCN Clinical Practice Guidelines in Oncology. Testicular Cancer V Continue.
Clinical in Oncology Testicular Cancer V.1.2010 Continue www.nccn.g TOC * Robert J. Motzer, MD/Chair Þ Memial Sloan-Kettering Cancer Center Neeraj Agarwal, MD Huntsman Cancer Institute at the University
More informationGERM CELL TUMOUR PI GC-1
GERM CELL TUMOUR PI GC-1 NCCN Pacific Island Working Group Clinical Members Scott Macfarlane Peter Bradbeer Jane Skeen Rob Corbett Radhika Sandilya Page 1 2 TREATMENT OUTLINE 6* cycles of identical treatment
More informationHematopoietic Cell Transplantation in the Treatment of Germ- Cell Tumors
Medical Policy Manual Transplant, Policy No. 45.38 Hematopoietic Cell Transplantation in the Treatment of Germ- Cell Tumors Next Review: August 2018 Last Review: December 2017 Effective: January 1, 2018
More informationAnalysis of the prognosis of patients with testicular seminoma
ONCOLOGY LETTERS 11: 1361-1366, 2016 Analysis of the prognosis of patients with testicular seminoma WEI DONG 1, WANG GANG 1, MIAOMIAO LIU 2 and HONGZHEN ZHANG 2 1 Department of Urology; 2 Department of
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More information17 th ESO-ESMO Masterclass in clinical Oncology
17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated
More informationNCCN Clinical Practice Guidelines in Oncology. Testicular Cancer V Continue
TOC Clinical in Oncology Testicular Cancer V.2.2010 Continue www.nccn.g Version 2.2010, 04/26/10 2010 National Comprehensive Cancer Netwk, Inc. All rights reserved. These guidelines and this illustration
More informationTesticular Germ Cell Tumors; A Simplistic Approach
Testicular Germ Cell Tumors; A Simplistic Approach Merce Jorda, MD, PhD, MBA Professor and Vice Chair, Director of Anatomic Pathology Director of Genitourinary Pathology Service Interim Director of Cytopathology
More informationProspective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors (SIOPCNSGCTII)
1 von 9 10.12.2013 09:03 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: UKM08_0057 Previous Study Return to List Next Study Prospective Trial for the Diagnosis and Treatment
More informationHematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors
Hematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors Policy Number: Original Effective Date: MM.07.020 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 12/16/2016
More information